How often do you refer patients for molecular profiling of a malignant tumor? For which of the following tumor types would you be most likely to recommend molecular profiling? Answer these questions and more.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Related Content

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

Ariana Pelosci

September 17th 2025

Article

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD

September 17th 2025

Podcast

A statistically significant difference was observed between the 2 groups in patients who received second-line therapy.

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Tim Cortese

September 17th 2025

Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

September 17th 2025

Podcast

Understanding Palliative and End-Of-Life Care in Oncology

Julie M. Vose, MD, MBA

September 17th 2025

Article

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

When Do You Recommend Molecular Profiling of Tumors?

Newsletter